Keane Pearse A, Chang Karen T, Liakopoulos Sandra, Jivrajka Renu V, Walsh Alexander C, Sadda Srinivas R
Doheny Image Reading Center, Doheny Eye Institute, Keck School of Medicine of University of Southern California, Los Angeles, California 90033, USA.
Retina. 2009 May;29(5):592-600. doi: 10.1097/IAE.0b013e31819b17a5.
To determine the characteristics of patients with neovascular age-related macular degeneration who show initial anatomic improvements on optical coherence tomography in response to treatment with ranibizumab, but who subsequently regress toward their anatomic baseline.
Data from 50 consecutive patients, receiving ranibizumab therapy for neovascular age-related macular degeneration, were collected. Raw StratusOCT images were analyzed using custom software ("OCTOR"). Changes in volume of neurosensory retina at months 1, 3, and 6 were calculated. Baseline demographic and morphologic characteristics were compared.
Forty-two patients (84%) showed a reduction in total retinal volume 1 month after initial treatment with ranibizumab. Of the patients that initially showed a reduction, 16 (38%) maintained this reduction through month 6, whereas 26 patients (62%) demonstrated a subsequent increase in retinal volume. Patients who maintained a reduction in edema received 3.75 +/- 1.18 injections of ranibizumab versus 2.96 +/- 1.34 injections for patients who did not (P = 0.049). Regression of initial anatomic improvements was associated with worsening of visual acuity (r = 0.599, P = 0.002).
Patients receiving fewer injections of ranibizumab appeared less likely to maintain anatomic improvements achieved following commencement of ranibizumab therapy; regression of these improvements was associated with deterioration in visual acuity.
确定接受雷珠单抗治疗后，在光学相干断层扫描中显示出初始解剖学改善，但随后又回归至解剖学基线的新生血管性年龄相关性黄斑变性患者的特征。
收集了50例连续接受雷珠单抗治疗新生血管性年龄相关性黄斑变性患者的数据。使用定制软件（“OCTOR”）分析原始StratusOCT图像。计算第1、3和6个月时神经感觉视网膜体积的变化。比较基线人口统计学和形态学特征。
42例患者（84%）在初次接受雷珠单抗治疗1个月后视网膜总体积减少。在最初显示体积减少的患者中，16例（38%）至第6个月时仍保持减少，而26例患者（62%）随后视网膜体积增加。水肿持续减轻的患者接受了3.75±1.18次雷珠单抗注射，未减轻的患者接受了2.96±1.34次注射（P = 0.049）。初始解剖学改善的消退与视力恶化相关（r = 0.599，P = 0.002）。
接受雷珠单抗注射次数较少的患者似乎不太可能维持雷珠单抗治疗开始后所取得的解剖学改善；这些改善的消退与视力恶化相关。
